AUTHOR=Zhou Shu-Guang , Wu Dai-Fei , Yao Hui , Zhang Wei-Yu , Tian Feng-Jiao , Chen Guo , Zhang Chun-Fa 

TITLE=REBACIN® inhibits E6/E7 oncogenes in clearance of human papillomavirus infection

JOURNAL=Frontiers in Oncology

VOLUME=12

YEAR=2022

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.1047222

DOI=10.3389/fonc.2022.1047222

ISSN=2234-943X

ABSTRACT=<p>Previous studies have demonstrated that REBACIN<sup>®</sup> intervention eliminates persistent high-risk human papillomavirus (hrHPV) infection. The initial establishment and subsequent progression of cervical cancer mainly depends on two major oncogenes, E6/E7, and previous studies have proposed E6/E7 oncogenes as a target for therapeutic drug development. The aim of this study was to investigate <italic>in vitro</italic> and <italic>in vivo</italic> whether REBACIN<sup>®</sup> inhibits E6/E7 oncogenes for elucidating the mechanism of REBACIN<sup>®</sup> in the clearance of persistent hrHPV infection. <italic>In vitro</italic>, after REBACIN<sup>®</sup> treatment, the growth of both Ca Ski and HeLa cervical cancer cells containing the E6/E7 oncogenes was prevented. In line with this finding is that E6/E7 expression was inhibited, which can be counteracted by the co-application of anti-REBACIN<sup>®</sup> antibody. These studies demonstrated that REBACIN<sup>®</sup> can effectively inhibit the growth of cervical cancer cells <italic>via</italic> targeting HPV E6/E7 expression. To further verify this finding in clinic, 108 volunteer patients with persistent hrHPV infections were randomly divided into REBACIN<sup>®</sup>, recombinant human interferon alpha-2b (Immunological drug control), or no-treatment blank control groups, received intravaginal administration of REBACIN<sup>®</sup>, interferon or no-treatment every other day for three months, and then followed up for E6/E7 mRNA assay. In REBACIN<sup>®</sup> group, 68.57% of patients showed complete clearance of HPV E6/E7 mRNA, which was significantly higher compared to 25.00% in the interferon immunological drug control group and 20.00% in blank control group, confirming that REBACIN<sup>®</sup> is potently efficacious on clearing persistent hrHPV infections <italic>via</italic> inhibition of HPV E6/E7 oncogenes.</p><sec><title>Clinical trial registration</title><p><uri xlink:href="http://www.chictr.org.cn/historyversionpuben.aspx?regno=ChiCTR2100045911" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.chictr.org.cn/historyversionpuben.aspx?regno=ChiCTR2100045911</uri>, identifier ChiCTR2100045911.</p></sec>